1st Patient Dosed in Trial of IPF Therapy Candidate Taladegib

1st Patient Dosed in Trial of IPF Therapy Candidate Taladegib

307179

1st Patient Dosed in Trial of IPF Therapy Candidate Taladegib

A Phase 2 clinical trial evaluating Endeavor BioMedicines’ experimental oral therapy taladegib (ENV-101) in people with idiopathic pulmonary fibrosis (IPF), has dosed its first patient. The trial (NCT04968574) is enrolling adults, ages 40 and older, with mild-to-moderate IPF at one Australian site, with at least three more expected to open in the country. “There are currently no approved therapies that stop the progression of fibrosis [tissue scarring] or treat the underlying causes of the disease,”…

You must be logged in to read/download the full post.